Compare CRTO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | NVAX |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.6M | 1.6B |
| IPO Year | 2013 | 1996 |
| Metric | CRTO | NVAX |
|---|---|---|
| Price | $17.21 | $8.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 9 |
| Target Price | ★ $35.90 | $11.33 |
| AVG Volume (30 Days) | 275.2K | ★ 4.4M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.95 | ★ 309.76 |
| EPS | ★ 2.64 | 2.58 |
| Revenue | ★ $2,296,692,000.00 | $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | $6.69 | ★ $3.47 |
| Revenue Growth | 27.65 | ★ 64.69 |
| 52 Week Low | $16.15 | $5.01 |
| 52 Week High | $36.06 | $11.85 |
| Indicator | CRTO | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 38.12 |
| Support Level | $16.15 | $8.01 |
| Resistance Level | $21.32 | $9.05 |
| Average True Range (ATR) | 0.71 | 0.54 |
| MACD | -0.04 | -0.23 |
| Stochastic Oscillator | 21.63 | 1.81 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.